Navigation Links
ChanTest hires Chris Mathes as Chief Commercial Officer

CLEVELAND, Aug. 17, 2012 /PRNewswire/ -- Today ChanTest announces the hiring of Chris Mathes, Ph.D., M.B.A. to lead its business into a new era. Mathes starts September 1st as Chief Commercial Officer (CCO) and will oversee all sales, marketing and customer relations activities at ChanTest. He will also contribute to the forward looking and strategic guidance of ChanTest as a global player in the CRO industry.

(Photo: )

"Chris is a real ion channel guy," said Dr. Arthur "Buzz" Brown, CEO, President & Founder of ChanTest. "As CCO, he brings a unique mix of science and business to our company in order to make ChanTest's interface to the world even better."

Dr. Mathes has a Ph.D. in Neuroscience from UCLA and an MBA from Rutgers University. He has published several ion channel papers in peer reviewed journals over the past two decades.  In the last 10 years, Mathes has been a pioneer in the development and implementation of automated patch clamp systems for ion channel safety testing and drug discovery. 

"I'm really excited about this opportunity at ChanTest," Mathes said. "ChanTest is already the market leading ion channel CRO. My goal is to further enhance the brand and to expand the business.  I want to make sure that every pharmaceutical or biotech lab in the world accesses the ion channel and scientific expertise available at ChanTest."

About ChanTest Corporation (

ChanTest translates the most advanced Ion Channel, GPCR and Transporter technologies to provide safer, more effective medicines. By combining electrophysiology, molecular biology and cell culture including cell lines, stem cells and native cells ChanTest has developed biomarkers, reagents and services that greatly enhance drug discovery. The Company has alliances in which its technologies are integrated with medicinal, combinatorial and computational chemistry, animal models and clinical trials to provide modular or complete services along the drug development pathway. Since its inception in 1998, ChanTest has tested compounds for more than 500 global pharmaceutical and biotechnology companies. ChanTest's library of  ion channel cell lines, validated human stem cell-derived cardiomyocytes and  predictive nonclinical cardiac risk assessment program are  the most comprehensive available today. Because of ChanTest's seminal role in cardiac safety and its uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail

CONTACT: Kate Siver, +1-216-332-1665,

SOURCE ChanTest Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
2. Health Revenue Assurance Associates Hires Valerie Rinkle as Vice President of Revenue Integrity Informatics
3. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
4. NHD Hires Ron Cronin as Executive Director
5. Millstone Medical Outsourcing Hires New Vice President Quality
6. Zimmer Holdings Names Christopher Begley to Board of Directors
7. Doug Pepper appointed as Chief Financial Officer at Cardiac Science
8. ADVENTRX Announces Appointment Of Chief Medical Officer
9. Accelr8 Appoints Steve Reichling Chief Financial Officer
10. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
11. Qforma Chief Technologist Honored as One of PharmaVOICE Magazines "100 Most Inspiring People in the Life Sciences"
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology:
(Date:11/28/2015)... Aliso Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... 30 new fully customizable media panels to choose from, the possibilities are endless. Users ... angle, and more. With the ProPanel: Pulse masking effects, users are sure to get ...
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
Breaking Medicine News(10 mins):